回盛生物
(300871)
| 流通市值：24.14亿 | | | 总市值：24.15亿 |
| 流通股本：1.66亿 | | | 总股本：1.66亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 206,809,092.09 | 1,019,758,798.36 | 691,386,248.86 | 449,082,426.69 |
| 营业收入 | 206,809,092.09 | 1,019,758,798.36 | 691,386,248.86 | 449,082,426.69 |
| 二、营业总成本 | 219,314,493.26 | 1,016,321,252.34 | 689,038,689.93 | 441,156,049.35 |
| 营业成本 | 159,934,252.24 | 806,465,634.79 | 544,725,663.44 | 348,738,072.54 |
| 税金及附加 | 2,307,708.03 | 9,529,403.11 | 6,546,315.16 | 4,225,093.91 |
| 销售费用 | 14,341,963.29 | 55,628,365.22 | 40,862,437.82 | 26,281,353.58 |
| 管理费用 | 18,413,255.46 | 75,680,149.1 | 52,054,568.67 | 33,609,313.79 |
| 研发费用 | 14,535,112.78 | 44,597,573.76 | 31,206,491.12 | 19,240,228.48 |
| 财务费用 | 9,782,201.46 | 24,420,126.36 | 13,643,213.72 | 9,061,987.05 |
| 其中:利息费用 | 10,410,980.81 | 28,215,682.33 | 16,618,173.07 | 10,413,382.7 |
| 其中:利息收入 | 777,622.73 | 4,349,899.17 | 3,290,618.03 | 1,592,966.96 |
| 加:公允价值变动收益 | -18,092,751.86 | 12,252,419.77 | 4,270,265.74 | 3,858,963.41 |
| 加:投资收益 | 3,345,414.97 | 13,122,321.17 | 6,094,052.68 | 3,189,297.17 |
| 资产减值损失(新) | -2,036,523.66 | -2,643,840.37 | -2,865,978.48 | -1,867,459.85 |
| 信用减值损失(新) | 4,174,706.75 | -25,161,815.83 | 518,366.31 | 1,866,982.49 |
| 其他收益 | 3,627,361.16 | 14,076,355.18 | 6,624,829.82 | 4,642,625.96 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -21,487,193.81 | 15,082,985.94 | 16,989,095 | 19,616,786.52 |
| 加:营业外收入 | 43,056.73 | 208,713.44 | 40,708.39 | 40,561.89 |
| 减:营业外支出 | 101,862.98 | 2,850,153.76 | 2,389,172.21 | 2,294,136.28 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -21,546,000.06 | 12,441,545.62 | 14,640,631.18 | 17,363,212.13 |
| 减:所得税费用 | -5,140,383.26 | -4,339,273.15 | -236,727.23 | 1,465,267.97 |
| 六、净利润 | -16,405,616.8 | 16,780,818.77 | 14,877,358.41 | 15,897,944.16 |
| 持续经营净利润 | -16,405,616.8 | 16,780,818.77 | 14,877,358.41 | 15,897,944.16 |
| 归属于母公司股东的净利润 | -16,405,616.8 | 16,780,818.77 | 14,877,358.41 | 15,897,944.16 |
| (一)基本每股收益 | -0.1 | 0.1 | 0.09 | 0.1 |
| (二)稀释每股收益 | -0.1 | 0.1 | 0.09 | 0.1 |
| 九、综合收益总额 | -16,405,616.8 | 16,780,818.77 | 14,877,358.41 | 15,897,944.16 |
| 归属于母公司股东的综合收益总额 | -16,405,616.8 | 16,780,818.77 | 14,877,358.41 | 15,897,944.16 |
| 公告日期 | 2024-04-25 | 2024-04-25 | 2023-10-30 | 2023-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |